GLP-1 Weight Loss in 2027: What’s Coming in 2027?
A few years ago, weight-loss medication mostly meant a weekly injection.
Now, there are pills, higher-dose options, medications that target two or three hormones at once, and experimental treatments designed to help protect muscle while you lose weight.
And some of the numbers coming out of recent studies are big.
One experimental drug helped participants lose an average of 28.3% of their body weight in 80 weeks. Another experimental combination produced 23.3% average weight loss in just 48 weeks in a trial involving people with type 2 diabetes. And the first GLP-1 pill for weight management is already available in the U.S.
So what could GLP-1 weight-loss in 2027 look like?
1. The Goal Is Getting Bigger Than Just “Lose More Weight”
Today's medications can already produce significant weight loss.
But researchers are now asking a different question:
Can we help people lose weight while making the overall treatment better?
That could mean protecting more muscle, making medication easier to take, offering more choices and finding treatments that work differently for different people.
One example is an experimental drug called trevogrumab. When researchers combined it with semaglutide, participants lost less muscle than those taking semaglutide alone. At 26 weeks, muscle-mass loss was about 3.3% with the combination compared with 6.7% with semaglutide alone. The combination preserved more than 70% of the muscle mass that otherwise would have been lost in the trial.
That's important because the future of weight loss may not just be about how much weight you lose, but what kind of weight you're losing.
2. New Drugs Are Targeting 2 – or Even 3 – Hormones at Once
Here's where things get especially interesting.
Semaglutide – the medication in Wegovy – works primarily through GLP-1.
Tirzepatide – the medication in Zepbound – targets two hormone receptors: GLP-1 and GIP.
Now researchers are testing medications that target three – one of the biggest names to watch is retatrutide. It targets: GLP-1 + GIP + glucagon.
You don't need to understand all three hormones to understand why researchers are excited about it. The idea is essentially to influence several systems involved in hunger, metabolism and weight at the same time.
And the results have attracted a lot of attention.
In a Phase 3 trial, people taking the highest dose of retatrutide lost an average of:
70.3 pounds — or 28.3% of their body weight — over 80 weeks.
Among participants who started with a BMI of 35 or higher and continued in an extension of the study, average weight loss reached:
85 pounds — or 30.3% — at 104 weeks.
And 45.3% of people taking the highest dose had lost at least 30% of their starting body weight by week 80.
Retatrutide is still experimental – it is not currently an FDA-approved weight-loss medication.
But numbers like these show just how quickly the science is moving.
3. We're Also Seeing Completely New Combinations
Triple-hormone drugs aren't the only thing coming.
Researchers are also looking at another hormone called amylin, which plays a role in helping your brain recognize that you're full.
One recent example is an experimental combination of tirzepatide + eloralintide, an amylin-based treatment.
In a Phase 2 study involving people with obesity or overweight and type 2 diabetes, participants taking the combination lost an average of up to: 23.3% of their body weight in 48 weeks. Those taking tirzepatide alone lost 14.8% over the same period. That's almost a 9 percentage-point difference.
But there's an important reality check: more powerful doesn't automatically mean easier.
Up to 27% of participants discontinued treatment in some combination groups, largely because of gastrointestinal side effects during dose escalation.
So the race isn't simply about creating the drug that causes the most weight loss.
It's about finding the right balance between results, side effects and long-term use.
4. Weight-Loss Medication Doesn't Necessarily Mean an Injection Anymore
This change has already happened.
The Wegovy pill became the first oral GLP-1 medication approved in the U.S. specifically for chronic weight management in late 2025 and launched in January 2026.
And its results aren't small.
In its Phase 3 trial, people who stayed on treatment lost an average of 16.6% of their body weight over 64 weeks. About 1 in 3 reached at least 20% weight loss in the trial analysis of participants who adhered to treatment.
The pill also took off quickly: Novo Nordisk reported more than 3 million prescriptions in its first five months after the U.S. launch.
For people who have been interested in GLP-1s but don't like the idea of giving themselves an injection, that's a major change.
5. There Could Be A LOT More Choices
Wegovy and Zepbound may be the names everyone knows now. But, that list could look very different over the next few years.
Drug companies are testing: pills, once-weekly injections, monthly injections, dual-hormone drugs, triple-hormone drugs, amylin combinations and treatments designed to preserve muscle.
And this is becoming a huge market. Analysts cited by Reuters estimate that the global obesity-drug market could eventually reach around $100 billion a year.
That level of competition means drugmakers have a big incentive to develop treatments that aren't simply another version of what's already available.
6. Weight-Loss Treatment Could Become Much More Personal
This may ultimately be the biggest change.
Right now, someone considering medication might ask:
“Should I take semaglutide or tirzepatide?”
In the future, there could be many more questions:
Would you prefer a pill or an injection?
How much weight are you hoping to lose?
Are you especially concerned about maintaining muscle?
How well do you tolerate certain side effects?
Do you have other weight-related health concerns?
How is your body responding to your current treatment?
With more medications and different ways of targeting weight, providers may eventually have far more options for matching a treatment to the individual.
And that's important because there isn't one “best” weight-loss medication for everyone.
So, Should You Wait Until 2027 to Start?
Not necessarily.
It's exciting to hear about drugs producing 20%, 25% or even 30% average weight loss in clinical trials.
But some of the most exciting medications we're talking about are still being studied. Trial results don't guarantee FDA approval, availability, or the same results for every person.
Meanwhile, medically guided weight-loss options are already available today.
With eMI's GLP-1 Weight Loss Program, you can start by completing a simple online assessment. A licensed healthcare provider reviews your information and, if treatment is medically appropriate, helps determine an option that makes sense for you.
And medication isn't the entire program.
You'll also have access to ongoing medical support, Care Coaching, progress tracking and eMI's AI Weight Loss Simulator to help you visualize potential changes and follow your progress over time.
Weight-loss medication may look very different a few years from now.
But one thing is already changing: weight loss is becoming less about simply trying harder – and more about finding the right support for your body.
Comments